The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy
Open accessAbstract
The ErbB2 ( Her2 ) proto-oncogene encodes a receptor tyrosine kinase, which is frequently amplified and overexpressed in human tumors. ErbB2 provides the target for a novel and effective antibody-based therapy (Trastuzumab/Herceptin) used for the treatment of mammary carcinomas. However, cardiomyopathies develop in a proportion of patients treated with Trastuzumab, and the incidence of such complications is increased by combination with standard chemotherapy. Gene ablation studies have previously demonstrated that the ErbB2 receptor, together with its coreceptor ErbB4 and the ligand Neuregulin-1, are essential for normal development of the heart ventricle. We use here Cre- lox P technology to mutate ErbB2 specifically in ventricular cardiomyocytes. Conditional mutant mice develop a severe dilated cardiomyopathy, with signs of cardiac dysfunction generally appearing by the second postnatal month. We infer that signaling from the ErbB2 receptor, which is enriched in T-tubules in cardiomyocytes, is crucial for adult heart function. Conditional ErbB2 mutant mice provide a model of dilated cardiomyopathy. In particular, they will allow a rigorous assessment of the role of ErbB2 in the heart and provide insight into the molecular mechanisms that underlie the adverse effects of anti-ErbB2 antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Prenzel, N., Zwick, E., Daub, H., Leserer, M., Abraham, R., Wallasch, C., & Ullrich, A. (1999) · Nature · doi:10.1038/47260 · Cited by 1,504
Multiple essential functions of neuregulin in development
Meyer, D., & Birchmeier, C. (1995) · Nature · doi:10.1038/378386a0 · Cited by 1,262
Self-citationThe Genetic Basis for Cardiomyopathy
Seidman, J. G., & Seidman, C. (2001) · Cell · doi:10.1016/s0092-8674(01)00242-2 · Cited by 1,046
Molecular and Cellular Mechanisms of Cardiac Arrhythmias
Keating, M. T., & Sanguinetti, M. C. (2001) · Cell · doi:10.1016/s0092-8674(01)00243-4 · Cited by 1,001
Signaling Pathways for Cardiac Hypertrophy and Failure
Hunter, J. J., & Chien, K. R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910213411706 · Cited by 869
Self-citationHirota, H., Chen, J., Betz, U. A. K., Rajewsky, K., Gu, Y., Ross, J., Müller, W., & Chien, K. R. (1999) · Cell · doi:10.1016/s0092-8674(00)80729-1 · Cited by 656
Self-citationNonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski, M. X., Ja, L., Gd, L., Te, H., FENDLY, B. M., & Fox, J. A. (1999) · PubMed · Cited by 653
Z/AP, a Double Reporter for Cre-Mediated Recombination
Lobe, C. G., Koop, K. E., Kreppner, W., Lomeli, H., Gertsenstein, M., & Nagy, A. (1999) · Developmental Biology · doi:10.1006/dbio.1999.9209 · Cited by 528
Cited by
MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy
Halkein, J., Tabruyn, S. P., Ricke-Hoch, M., Haghikia, A., Nguyen, N.-Q.-N., Scherr, M., Castermans, K., Malvaux, L., Lambert, V., Thiry, M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64365 · Cited by 499
Single-cell transcriptomics reveals cell-type-specific diversification in human heart failure
Koenig, A. L., Shchukina, I., Amrute, J., Andhey, P. S., Zaitsev, K., Lai, L., Bajpai, G., Bredemeyer, A., Smith, G., Jones, C., et al. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00028-6 · Cited by 482
Understanding, recognizing, and managing toxicities of targeted anticancer therapies
Dy, G. K., & Adjei, A. A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21184 · Cited by 331
Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: Old drug with a new vision
Iqubal, A., Iqubal, M. K., Sharma, S., Ansari, M. A., Najmi, A. K., Ali, S. M., Ali, J., & Haque, S. E. (2019) · Life Sciences · doi:10.1016/j.lfs.2018.12.018 · Cited by 328
Gorini, S., De Angelis, A., Berrino, L., Malara, N., Rosano, G., & Ferraro, E. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/7582730 · Cited by 325
Metadata
- Authors
- Özcelik, C., Erdmann, B., Pilz, B., Wettschureck, N., Britsch, S., Hübner, N., Chien, K. R., Birchmeier, C., & Garratt, A. N.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2002-06-18
- Volume
- 99
- Issue
- 13
- Pages
- 8880-8885
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1983530651
- Cited by
- 473
- References
- 44
- FWCI
- 13.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. https://app.cochat.ai/papers/10.1073/pnas.122249299
- The paper
- Özcelik, C., Erdmann, B., Pilz, B., Wettschureck, N., Britsch, S., Hübner, N., Chien, K. R., Birchmeier, C., & Garratt, A. N. (2002). Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.122249299
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
